GENE ONLINE|News &
Opinion
Blog

R&D
Pembrolizumab Upstages Topline PD-1/L1 drugs in lung cancer tussle
2018-11-06
Update on Tuberculosis containment using vaccine – Taming the disease
2018-10-26
M&A
Targeted cancer radiopharma specialist – ENDOCYTE INC.’s acquisition
2018-10-23
Roche’s breast cancer drug, Kadcyla succeeds phase III trial
2018-10-22
Finding new pharmacological approach for neuroblastoma treatment
2018-10-16
Tracking “OFF THE SHELF” CAR-T Cell therapy & an IPO worth $100M
2018-10-15
R&D
A new player emerges in the non-small cell lung cancer (NSCLC) therapy scene
2018-10-11
Long term HIV suppression by new combination therapy
2018-10-01
Clash of three migraines medications & cost benefit for patients
2018-10-01
CRISPR mediated overexpression of cocaine hydrolyzing enzyme in mouse skin patch protects against lethal overdose
2018-09-20
Latest Developments in Precision Medicine and Molecular Detection
2018-09-19
Transposon sheds light on genes associated with developmental brain diseases
2018-08-15
A longevity chronicle: The development of anti-aging pill
2018-08-14
1 32 33 34
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top